You're contacting media contact of this press release

Title: ENCLONY Expands Automated Visual Inspection Tech as Pharmaceutical Production Speeds Accelerate

Seoul, South Korea, 15th Oct 2026  – As pharmaceutical manufacturing processes become increasingly automated and production speeds rise, automated visual inspection (AVI) is becoming essential for ensuring the quality of tablets and capsules.Visual inspection in pharmaceutical production goes beyond checking product appearance. During manufacturing, tablets and capsules can develop various defects, including chipping, cracks, foreign matter, discoloration, coating irregularities, and printing errors. Detecting these defects before shipment and selecting only compliant products is a vital step in pharmaceutical quality management.Above all, this process is crucial for patient safety. Broken or chipped tablets and capsules with compromised contents do not represent acceptable product quality. Foreign matter or contamination poses severe hygiene and safety concerns, while cracked or peeling coatings can directly impact drug efficacy. For enteric-coated or sustained-release formulations designed to control the release site and rate of active ingredients, coating integrity is directly linked to product function. Defective coating may cause active ingredients to release too quickly or too slowly, affecting both safety and therapeutic outcomes. Therefore, visual inspection is a necessary quality assurance process to ensure patients receive medications that meet intended performance standards.From a manufacturer’s perspective, consistent quality builds corporate and brand trust. Pharmaceutical companies exporting to international markets must stably meet quality standards across different regions. Defective products reaching the market can cause customer complaints, costly recalls, returns, and loss of business trust, making pre-shipment screening vital.ENCLONY Co., Ltd.,...

This press release is issued by King Newswire